VIVUS, Inc. To Present At Healthcare Investment Conferences In November

MOUNTAIN VIEW, Calif., Oct. 31 /PRNewswire-FirstCall/ -- VIVUS, Inc. , a specialty pharmaceutical company focused on the research, development and commercialization of products to restore sexual function in women and men, today announced that Timothy Morris, VIVUS' Chief Financial Officer, will make a presentation at two investment conferences in November. On November 8, Mr. Morris will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at 10:10 a.m. Eastern Time in the New York Palace Hotel in New York City. On November 10 at 2:00 p.m. local time, Mr. Morris will present at SG Cowen's 6th Annual Global Healthcare Conference at the Hilton Diagonal Mar Hotel in Barcelona, Spain. Both presentations will be webcast and available for viewing after each conference on the investor relations page of VIVUS' website at


VIVUS, Inc. is a pioneer in the research and development of proprietary products to restore sexual function for women and men. VIVUS' current product pipeline includes four investigational products in late stage clinical development. For women, VIVUS has initiated a Phase 2B program with ALISTA(TM) for female sexual arousal disorder and a Phase 3 program for Evamist(TM) for the alleviation of menopausal symptoms. Testosterone MDTS(R) for the treatment of hypoactive sexual desire disorder has completed Phase 2 development. The MDTS system is a patented new-generation, transdermal drug delivery technology that delivers drugs through the skin. For men, VIVUS is developing avanafil for erectile dysfunction, which has completed Phase 2 development. VIVUS currently markets MUSE(R) (alprostadil) suppository for the treatment of erectile dysfunction in the U.S. and internationally through distributors. For more information on clinical trials and products, please visit the Company's web site at

For more information: VIVUS, Inc. Timothy E. Morris 650-934-5200


CONTACT: Timothy E. Morris of VIVUS, Inc., +1-650-934-5200

Back to news